Outcome of Tongue Cancer Treated with Surgery and Postoperative Radiotherapy

DOI Web Site 5 Citations 14 References
  • Suzuki Motoyuki
    Department of Otolaryngology, Head and Neck Surgery Osaka Medical Center for Cancer and Cardiovascular Diseases
  • Yoshino Kunitoshi
    Department of Otolaryngology, Head and Neck Surgery Osaka Medical Center for Cancer and Cardiovascular Diseases
  • Fujii Takashi
    Department of Otolaryngology, Head and Neck Surgery Osaka Medical Center for Cancer and Cardiovascular Diseases
  • Yoshii Masashi
    Department of Otolaryngology, Head and Neck Surgery Osaka Medical Center for Cancer and Cardiovascular Diseases
  • Sugawa Toshimitsu
    Department of Otolaryngology, Head and Neck Surgery Osaka Medical Center for Cancer and Cardiovascular Diseases
  • Kitamura Koji
    Department of Otolaryngology, Head and Neck Surgery Osaka Medical Center for Cancer and Cardiovascular Diseases

Bibliographic Information

Other Title
  • 手術と術後照射による舌癌263例の治療成績
  • シュジュツ ト ジュツゴ ショウシャ ニ ヨル ゼツガン 263レイ ノ チリョウ セイセキ

Search this article

Abstract

A retrospective analysis of 263 patients with previously untreated squamous cell carcinoma of the tongue between 2000 and 2010 was performed. Those patients, who received preoperative chemotherapy, had a history of head and neck cancer or had previously received radiotherapy for the other disease, were excluded. All patients underwent a surgical procedure as a part of the initial treatment. Patients with close or microscopically involved margins of resection, INF (Infiltrative growth pattern) γ or at least two involved nodes were classified as high risk patients. Postoperative radiotherapy (PORT) was undertaken for the high risk patients. After a median follow-up of 72 months, the 5-year overall survival and 5-year cause-specific survival were as follows: 79.1%, 85.0% in all stages, 82.7%, 91.2% in Stage I (n=76), 86.7%, 89.0% in Stage II (n=98), 71.5%, 78.6% in Stage III (n=57), and 61.5%, 69.1% in Stage IV (n=32). Patients without high risk features had significantly higher overall survival rate than those in the case of high risk patients, despite receiving no PORT. For high risk patients, PORT significantly improved the locoreginal control rate, but the overall survival rate did not improve.

Journal

Citations (5)*help

See more

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top